Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

Nature Medicine

Volumn 1, Issue 9, 1995, Pages 938-943

  Mineta, Toshihiro ^a,b   Rabkin, Samuel D ^a   Yazaki, Takahito ^a   Hunter, William D ^a   Martuza, Robert L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; MARKER; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN TISSUE; INTRACEREBRAL DRUG ADMINISTRATION; MONKEY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMAL; AOTINAE; BETA-GALACTOSIDASE; BRAIN NEOPLASMS; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DEFECTIVE VIRUSES; GANCICLOVIR; GENE THERAPY; GENES, REPORTER; GLIOBLASTOMA; HUMAN; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; SAFETY; SIMPLEXVIRUS; SUPPORT, U.S. GOV'T, P.H.S.; TEMPERATURE; VERO CELLS; VIRAL PROTEINS; VIRULENCE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0029023868     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0995-938     Document Type: Article

References (35)

1. Mahaley, M.S. Jr, Mettlin, C., Natarajan, N., Laws, E.R. Jr and Peace, B.B. National survey of patterns of care for brain-tumor patients. J. Neurosurg. 71, 826-836 (1989).
2. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. and Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856 (1991).
3. Markert, J.M., Malick, A., Coen, D.M. and Martuza, R.L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 35, 597-603 (1993).
4. Mineta, T., Rabkin, S.D. and Martuza, R.L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966 (1994).
5. Kaplitt, M.G. et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neuro-Oncol. 19, 137-147 (1994).
6. Jia, W.W., McDermott, M., Goldie, J., Cyander, M., Tan, J. and Tufaro, F. Selective destruction of gliomas in immunocompetent rats by thymidine ki-nase-defective herpes simplex virus type 1. J. natn. Cancer Inst. 86, 1209-1215 (1994).
7. Boviatsis, E.J. etal. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1, 323-331 (1994).
8. Coen, D.M, et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeninal ganglia but do not reactivate. Proc. natn. Acad. Sci. U.S.A. 86, 4736-4740 (1989).
9. Goldstein, D.J. and Weller, S.K, Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant, J, Virol. 62, 196-205 (1988).
10. Chou, J., Kern, E.R., Whitley, R.J. and Roizman, B. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250, 1262-1266 (1990).
11. Preston, V.G., Palfreyman, J.W. and Duita, B.M. Identification of a herpes simplex virus type 1 polypeptide which is a component of the virus-induced ribonucleotide reductase, f.gen. Virol. 65, 1457-1466 (1984).
12. Jacobson, J.G. et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276-283 (1989).
13. Chou, J. and Roizman, B. The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component, J. Virol. 57, 629-637 (1986).
14. Dolan, A., McKie, E., MacLean, A.R. and McGeoch, D.J. Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17. J. gen. Virol. 73, 971-973 (1992).
15. Whitley, R.J., Kern, E.R., Chatterjee, S., Chou, J. and Roizman, B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 34.5 deletion mutants in rodent models. J. clin. Invest. 91, 2837-2843 (1993).
16. MacLean, A.R., Ul-Fareed, M., Robertson, L., Harland, J. and Brown, S.M. Herpes simplex virus type 1 variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence. J. gen. Virol. 72, 631-639 (1991).
17. Bolovan, C.A., Sawtell, N.M. and Thompson, R.L. ICP34.5 mutants of herpes simplex virus type 1 strain 17 syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol. 68, 48-55 (1994).
18. Ausubel, F.M. et al. Current Protocols in Molecular Biology (Wiley-Interscience, New York, 1991).
19. Southern, E.M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. molec. Biol. 98, 503-517 (1975).
20. Knipe, D.M., Batterson, W., Nosal, C, Roizman, B. and Buchan, A. Molecular genetics of herpes simplex virus. VI, Characterization of a temperature-sensitive mutant defective in the expression of all early viral gene products. J. Virol. 38, 539-547 (1981).
21. Goldstein, D.J. and Weller, S.K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 166, 41-51 (1988).
22. Coen, D.M., Goldstein, D.J. and Weller, S.K. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir, Antimicrob. Agents Chemother. 33, 1395-1399 (1989).
23. Yamada, Y. etal. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus typel in mice. J. infect. Dis. 164, 1091-1097 (1991).
24. Cameron, J.M. etal. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J. gen. Virol. 69, 2607-2612 (1988).
25. Hershkovitz, P. Two new species of night monkeys, genus Aotus (Cebidae, Platyrhini): A preliminary report on Aotus taxonomy. Am. J. Primatol. 4, 209-243 (1983).
26. Aikawa, M. et al. An atlas of renal disease in Aotus monkeys with experimental plasmodial infection (American Institute of Biological Sciences, Washington, DC, 1988).
27. Hunt, R.D. Herpesvirus simplex infection, in Nonhuman Primates, Vol. 1 (eds Jones, T.C., Mohr, U. and Hunt, R.D.) 82-86 (Springer, Berlin, 1993).
28. Katzin, D.S., Connor, J.D., Wilson, L.A. and Sexton, R.S. Experimental herpes simplex infection in the owl monkey. Proc. Soc. exp. Biol. Med. 125, 391-398 (1967).
29. Melendez, L.V., España, C., Hunt, R.D., Daniel, M.D. and Garcia, F.G. Natural herpes simplex infection in the owl monkey (Aotus trivirgatus). Lab. Anim. Care 19, 38-45 (1969).
30. Meignier, B., Martin, B., Whitley, R.J. and Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. infect. Dis. 162, 313-321 (1990).
31. Baringer, J.R. and Pisani, P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann. Neurol. 36, 823-829 (1994).
32. Asou, H., Hirano, S. and Kohsaka, S. Changes in ganglioside composition and morphological features during the development of cultured astrocytes from rat brain. Neurosci. Res. 6, 369-375 (1989).
33. McCarthy, K.D. and de Vellis, J. Preparation of separate astroglial and oligoden- droglial cell cultures from rat cerebral tissue. J. Cell Biol. 85, 890-902 (1980).
34. Messer, A. The maintenance and identification of mouse cerebellar granule cells in monolayer culture. Brain Res. 130, 12-23 (1977).
35. Kaplitt, M.G. et al. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Molec. cell. Neurosci. 2, 320-330 (1991).